Journal of Alzheimer s Disease,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 15, 2025
Background
The
amyloid
cascade
hypothesis
still
dominates
in
Alzheimer's
disease
(AD),
and
the
acceleration
of
clearance
efficiency
amyloid-β
(Aβ)
has
been
always
considered
as
an
effective
treatment
option
to
slow
occurrence
progression
AD.
Objective
This
study
aims
explore
role
zkscan3
its
related
pathways
AD
microglia-mediated
pathogenesis,
whether
combined
effect
drugs
can
exert
neuroprotective
function.
Methods
N9
mouse
microglia
HT-22
hippocampal
neurons
were
randomly
divided
into
6
groups,
qRT-PCR
technique
was
used
detect
gene
expression
level
genes
lysosome
generation
Fourteen
C57
mice
two
drug
intervention
model
selected
establish
from
group.
Transmission
electron
microscope
cell
status
function
hippocampus
together
with
other
groups.
Results
Compared
group,
group
downregulated,
degree
neuronal
injury
reduced,
structure
number
synapses
improved,
intracellular
enhanced.
Conclusions
Zkscan3
play
a
vital
development
CGRP
CHIT-1,
intervention,
imparts
effects
through
zkscan3-related
improve
lysosomal
certain
effects.
Frontiers in Aging Neuroscience,
Journal Year:
2025,
Volume and Issue:
16
Published: Jan. 7, 2025
Alzheimer's
disease
(AD)
is
a
complex
neurodegenerative
disorder,
with
amyloid-beta
(Aβ)
aggregation
playing
key
role
in
its
pathogenesis.
Aβ-induced
oxidative
stress
leads
to
neuronal
damage,
mitochondrial
dysfunction,
and
apoptosis,
making
antioxidative
strategies
promising
for
AD
treatment.
This
study
investigates
the
effects
of
hydrogen-rich
water
(HRW)
zebrafish
model.
Zebrafish
were
exposed
aluminum
chloride
induce
AD-like
pathology
then
treated
HRW
using
nanobubble
device.
Behavioral
assays,
ELISA,
Hematoxylin-eosin
(H&E)
staining,
reactive
oxygen
species
(ROS)
neutrophil
fluorescence
labeling
employed
assess
HRW's
impact.
Additionally,
16S
rRNA
sequencing
analyzed
effect
on
gut
microbiota.
can
significantly
improve
cognitive
impairment
depression-like
behavior
model,
reduce
Aβ
deposition
(p
<
0.0001),
regulate
liver
Soluble
epoxide
hydrolase
(sEH)
levels
0.05),
neuroinflammation,
stress.
Furthermore,
reduced
number
harmful
bacteria
linked
by
restoring
balance
microbiota
gut.
These
findings
suggest
that
has
potential
as
therapeutic
strategy
targeting
stress,
inflammation,
gut-brain
axis
modulation.
Pharmaceuticals,
Journal Year:
2025,
Volume and Issue:
18(1), P. 104 - 104
Published: Jan. 15, 2025
Cytokine-mediated
inflammation
is
increasingly
recognized
for
playing
a
vital
role
in
the
pathophysiology
of
wide
range
brain
disorders,
including
neurodegenerative,
psychiatric,
and
neurodevelopmental
problems.
Pro-inflammatory
cytokines
such
as
interleukin-1
(IL-1),
tumor
necrosis
factor-alpha
(TNF-α),
interleukin-6
(IL-6)
cause
neuroinflammation,
alter
function,
accelerate
disease
development.
Despite
progress
understanding
these
pathways,
effective
medicines
targeting
are
still
limited.
Traditional
anti-inflammatory
immunomodulatory
drugs
peripheral
inflammatory
illnesses.
Still,
they
face
substantial
hurdles
when
applied
to
central
nervous
system
(CNS),
blood-brain
barrier
(BBB)
unwanted
systemic
effects.
This
review
highlights
developing
treatment
techniques
modifying
cytokine-driven
focusing
on
advances
that
selectively
target
critical
involved
pathology.
Novel
approaches,
cytokine-specific
inhibitors,
antibody-based
therapeutics,
gene-
RNA-based
interventions,
sophisticated
drug
delivery
systems
like
nanoparticles,
show
promise
with
respect
lowering
neuroinflammation
greater
specificity
safety.
Furthermore,
developments
biomarker
discoveries
neuroimaging
improving
our
ability
monitor
responses,
allowing
more
accurate
personalized
regimens.
Preclinical
clinical
trial
data
demonstrate
therapeutic
potential
tailored
techniques.
However,
significant
challenges
remain,
across
BBB
reducing
off-target
As
research
advances,
creation
personalized,
cytokine-centered
therapeutics
has
therapy
landscape
illnesses,
giving
patients
hope
better
results
higher
quality
life.
medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 21, 2025
Abstract
Anti-NMDAR1
autoantibodies
can
bind
NMDA
receptors
to
suppress
glutamate
excitotoxicity
in
the
brain.
Low
titers
of
blood
circulating
natural
anti-NMDAR1
were
reported
∼10%
general
human
population.
We
developed
a
new
method
more
accurately
quantify
these
low
autoantibodies.
After
quantifying
plasma
324
age–
and
sex-matched
subjects
(163
healthy
controls;
161
Alzheimer’s
disease
(AD)
patients),
I
found
that
AD
patients
carrying
higher
levels
have
significantly
(p
value:
0.003)
scores
Mini-Mental
State
Examination
(MMSE
score:
23.5)
than
lower
21.4).
No
significant
differences
MMSE
however
between
controls
with
either
or
autoantibodies,
indicating
little
harmful
effect
Consistently,
superior
cognitive
performances
comparison
These
data
suggest
may
neuroprotective
effects
against
decline
patients.
Receptors,
Journal Year:
2025,
Volume and Issue:
4(1), P. 2 - 2
Published: Jan. 26, 2025
Glucagon-like
peptide-1
receptor
agonists
(GLP-1RAs),
including
dulaglutide,
liraglutide,
semaglutide,
and
exenatide,
are
effective
treatments
for
type
2
diabetes
mellitus
(T2DM)
obesity.
These
agents
mimic
the
action
of
endogenous
incretin
glucagon-like
(GLP-1)
by
enhancing
insulin
secretion,
inhibiting
glucagon
release,
promoting
weight
loss
through
appetite
suppression.
GLP-1RAs
have
recently
been
suggested
to
neuroprotective
effects,
suggesting
their
potential
as
treatment
neurodegenerative
disorders,
such
Alzheimer’s
disease
(AD).
AD
T2DM
share
several
common
pathophysiological
mechanisms,
resistance,
chronic
inflammation,
oxidative
stress,
mitochondrial
dysfunction.
shared
mechanisms
suggest
that
therapeutic
targeting
metabolic
dysfunction
may
also
be
beneficial
conditions.
Preclinical
studies
on
in
models,
both
vitro
vivo,
demonstrated
promising
reductions
amyloid-beta
accumulation,
decreased
tau
hyperphosphorylation,
improved
synaptic
plasticity,
enhanced
neuronal
survival.
Despite
encouraging
results
from
preclinical
challenges
need
addressed
before
can
widely
used
treatment.
Ongoing
clinical
trials
investigating
cognitive
benefits
patients,
aiming
establish
role
a
option
AD.
This
review
aimed
examine
current
literature
GLP-1
